



## Donna J. Wren

SENIOR COUNSEL

267 223-6771 direct

[donna.wren@faberlawgroup.com](mailto:donna.wren@faberlawgroup.com)

### Industry Experience

#### **Founder**

The Wren Law Office

#### **Division Counsel**

Specialty Chemicals Group and Global Procurement Group  
FMC Corporation

#### **Senior Counsel**

GSK Legal Department, Business Development Transactions  
GlaxoSmithKline, Inc.

#### **Associate**

Saul Ewing LLP

Donna's clients benefit from her strong transactional background in the pharmaceutical and technology industries. She is able to provide the unique perspectives of both an in-house and outside counsel, having represented life sciences clients in complex research, development and licensing agreements. Donna's substantial experience also includes various matters with a global scope.

#### **EXPERIENCE**

##### **Solo Practitioner**

- Focused on clients in the pharmaceutical, chemical and technology industries

##### **GlaxoSmithKline (GSK)**

###### **In-House Counsel**

- Supported global business transactions for therapeutic, diagnostic and cell-based products, including option-based discovery, development and commercialization deals, sponsored research agreements, and early stage research collaborations and evaluation agreements
- Assisted in the establishment of strategic partnerships that included the company's major R&D alliances with Human Genome Sciences, Inc. and OncoMed Pharmaceuticals, and the integration of a mission-critical

#### **Bar Admissions**

- Pennsylvania

#### **Education**

- Ohio Northern University Claude W. Pettit College of Law, J.D., summa cum laude
- Fulbright Scholar to Valencia, Spain
- The Pennsylvania State University, B.S., with Honors



## Donna Wren (continued)

---

technology platform acquisition which greatly expanded GSK's compound screening capabilities

- Served as a division counsel for a large international chemical company supporting the company's Specialty Chemicals and Global Procurement Groups
- Handled development, license and commercialization agreements for novel technology used in the manufacture of alginate-based products for use in food, pharmaceutical and cosmetic applications

### RECENT CLIENT WORK

- Exclusive sublicense agreement between Odylia Therapeutics and PTC Therapeutics, Inc. to develop novel gene therapies in rare inherited retinal diseases utilizing the Anc80 vector system developed by researchers at Massachusetts Eye and Ear
- Service agreement for the collection of human biological samples for use by client in research and development of precision cancer immunotherapies
- SaaS agreement for access and use by client of cloud-based applications for use in client's worldwide clinical trials
- GMP manufacturing services agreements with various contract manufacturing organizations for the clinical manufacture of client's API/drug substance and packaging and labeling of clinical trial products
- Various exclusive license agreements with academic institutions to support clients' novel drug development efforts
- Collaboration Agreement between Synlogic, Inc. and Ginkgo Bioworks to combine Ginkgo Bioworks' automated foundry and expertise in high throughput organism screening and design with Synlogic's expertise in discovery, translational and clinical development of synthetic biotic medicines to accelerate development of novel gut-based therapeutics
- Exclusive License Agreement on behalf of Odylia Therapeutics, Inc., a non-profit corporation launched with support from Massachusetts Eye and Ear, to enable Odylia Therapeutics, Inc. to focus on the development of lab findings into clinical trials for ultra-rare genetic blindness
- Sponsored research agreements and advice with respect to several unique research arrangements with academic institutions for new biotech, including a strategic sponsored research agreement with the University of Pittsburgh

### COMMUNITY

Donna serves as a volunteer attorney with the Support Center for Child Advocates in Philadelphia, representing abused and neglected children.

